Skip to main content Skip to navigation
BV605 Mouse Anti-Human CD13
Alert icon
This on-demand reagent will be transitioning to a standard catalog equivalent in April 2024. Replacement SKU [569238] is available now. More Info #
Product Details
Down Arrow Up Arrow


BD OptiBuild™
ANPEP; APN; Aminopeptidase N; Alanyl aminopeptidase; LAP1; PEPN
Human (Tested in Development)
Mouse BALB/c X C57BL/6 IgG1, κ
KG-1a Cell Line
Flow cytometry (Qualified)
0.2 mg/ml
V MA21
AB_2742787
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

Product Notices

  1. This antibody was developed for use in flow cytometry.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Researchers should determine the optimal concentration of this reagent for their individual applications.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. BD Horizon Brilliant Violet 605 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
745191 Rev. 1
Antibody Details
Down Arrow Up Arrow
L138

The L138 monoclonal antibody (also known as Leu-M7) specifically binds to a glycosylated 150 kDa type II integral membrane zinc-metalloprotease. The CD13 antigen is also known as aminopeptidase N, APN, ANPEP, and gp150. The CD13 antigen is expressed on granulocytes, monocytes, mast cells, and granulocyte/macrophage progenitor cells (CFU-GM), but not on lymphocytes, platelets, or erythrocytes. It is expressed on most acute myeloid leukemia (AML) cells and some chronic myeloid leukemia (CML) cells. The CD13 antigen is also expressed on epithelial cells of the kidney, small intestine, and respiratory tract, as well as in synaptic membranes in the central nervous system (CNS). The CD13 antigen is involved in the metabolism of many regulatory peptides. Clustering of the CD13 antigen by various forms of ligation promotes the adhesion between monocytes and endothelial cells. The CD13 antigen is the receptor for human coronavirus 229E, the causative agent for some cases of upper respiratory infection.

This antibody is conjugated to BD Horizon™ BV605 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 407-nm and Em Max of 602-nm, BD Horizon BV605 can be excited by a violet laser and detected with a standard 610/20-nm filter set. BD Horizon BV605 is a tandem fluorochrome of BD Horizon BV421 and an acceptor dye with an Em max at 605-nm. Due to the excitation of the acceptor dye by the green (532 nm) and yellow-green (561 nm) lasers, there will be significant spillover into the PE and BD Horizon PE-CF594 detectors off the green or yellow-green lasers. BD Horizon BV605 conjugates are very bright, often exhibiting brightness equivalent to PE conjugates and can be used as a third color off of the violet laser.

745191 Rev. 1
Format Details
Down Arrow Up Arrow
BV605
The BD Horizon Brilliant Violet™ 605 (BV605) dye is part of the BD Horizon Brilliant Violet™ family of dyes. This tandem fluorochrome is comprised of a BV421 donor with an excitation maximum (Ex Max) of 407-nm and an acceptor dye with an emission maximum (Em Max) at 605-nm. BV605, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 610-nm (e.g., a 610/20-nm bandpass filter). The acceptor dye can be excited by the yellow-green (561-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
BV605
Violet 405 nm
407 nm
605 nm
745191 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (20)

  1. Gadd S. Cluster report: CD13. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989::782-784.
  2. Ashmun RA, Holmes KV, Shapiro LH, et al. CD13 (aminopeptidase N) cluster workshop report. In: Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995::771-775.
  3. Bradstock KF, Favaloro EJ, Kabral A, Kerr A, Hughes WG, Musgrove E. Myeloid progenitor surface antigen identified by monoclonal antibody.. Br J Haematol. 1985; 61(1):11-20. (Biology). View Reference
  4. Büchi G, Girotto M, Baldini G, et al. Differentiation phenotypes on cells of acute myeloid leukemia studied by My7, My9, My4, Mo1 and Ja monoclonal antibodies.. Pathologica. 79(1064):699-704. (Biology). View Reference
  5. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.. J Clin Oncol. 1990; 8(5):813-9. (Biology). View Reference
  6. Drexler HG. Classification of acute myeloid leukemias--a comparison of FAB and immunophenotyping.. Leukemia. 1987; 1(10):697-705. (Biology). View Reference
  7. Foon KA, Gale RP, Todd RF. Recent advances in the immunologic classification of leukemia.. Semin Hematol. 1986; 23(4):257-83. (Biology). View Reference
  8. Griffin JD, Ritz J, Beveridge RP, Lipton JM, Daley JF, Schlossman SF. Expression of MY7 antigen on myeloid precursor cells.. Int J Cell Cloning. 1983; 1(1):33-48. (Biology). View Reference
  9. Howard MR, Thomas L, Reid MM. Variable detection of myeloid antigens in childhood acute lymphoblastic leukaemia.. J Clin Pathol. 1994; 47(11):1006-9. (Clone-specific: Flow cytometry). View Reference
  10. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13).. Blood. 1999; 94(7):2333-42. (Biology). View Reference
  11. Lee SH, Crocker PR, Westaby S, et al. Isolation and immunocytochemical characterization of human bone marrow stromal macrophages in hemopoietic clusters.. J Exp Med. 1988; 168(3):1193-8. (Biology). View Reference
  12. Look AT, Ashmun RA, Shapiro LH, et al. Report on the CD13 (aminopeptidase N) cluster Workshop. In: Knapp W. W. Knapp .. et al., ed. Leucocyte typing IV : white cell differentiation antigens. Oxford New York: Oxford University Press; 1989:784-787.
  13. Mina-Osorio P, Winnicka B, O'Conor C, et al. CD13 is a novel mediator of monocytic/endothelial cell adhesion.. J Leukoc Biol. 2008; 84(2):448-59. (Biology). View Reference
  14. Pombo de Oliveira MS, Matutes E, Rani S, Morilla R, Catovsky D. Early expression of MCS2 (CD13) in the cytoplasm of blast cells from acute myeloid leukaemia.. Acta Haematol. 1988; 80(2):61-4. (Biology). View Reference
  15. Sakai K, Hattori T, Sagawa K, Yokoyama M, Takatsuki K. Biochemical and functional characterization of MCS-2 antigen (CD13) on myeloid leukemic cells and polymorphonuclear leukocytes.. Cancer Res. 1987; 47(21):5572-6. (Biology). View Reference
  16. Terstappen LW, Hollander Z, Meiners H, Loken MR. Quantitative comparison of myeloid antigens on five lineages of mature peripheral blood cells. J Leukoc Biol. 1990; 48(2):138-148. (Clone-specific: Flow cytometry). View Reference
  17. Yang P, Wang X. COVID-19: a new challenge for human beings.. Cell Mol Immunol. 2020; 17(5):555-557. (Biology). View Reference
  18. Yeager CL, Ashmun RA, Williams RK, et al. Human aminopeptidase N is a receptor for human coronavirus 229E.. Nature. 1992; 357(6377):420-2. (Biology). View Reference
  19. Zola H. Leukocyte and stromal cell molecules : the CD markers. Hoboken, N.J.: Wiley-Liss; 2007.
  20. van Dongen JJ, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012; 26(9):1908-1975. (Clone-specific: Flow cytometry). View Reference
View All (20) View Less
745191 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.